Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in Onchocerciasis-associated Epilepsy
NCT03052998Phase 4Completed
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ivermectin in onchocerciasis-associated epilepsy (OAE) (2 arms). Primary endpoint: Seizure freedom at 4 months. Started Oct 2017; status: completed.
02
Drugs
ivermectin
03
Conditions
onchocerciasis-associated epilepsy (OAE)
Beyond the preview
Go deeper on NCT03052998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052998.